Iovance Biotherapeutics (IOVA) – Research Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Iovance Biotherapeutics (NASDAQ: IOVA) recently:

  • 2/9/2018 – Iovance Biotherapeutics had its price target raised by analysts at Jefferies Group LLC to $31.00. They now have a “buy” rating on the stock.
  • 2/8/2018 – Iovance Biotherapeutics was given a new $22.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 2/2/2018 – Iovance Biotherapeutics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 2/2/2018 – Iovance Biotherapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 1/31/2018 – Iovance Biotherapeutics had its price target raised by analysts at Oppenheimer Holdings Inc. from $13.00 to $19.00. They now have an “outperform” rating on the stock.
  • 1/29/2018 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at Wells Fargo & Co. They now have a $23.00 price target on the stock.
  • 1/25/2018 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at B. Riley. They now have a $18.00 price target on the stock.
  • 1/25/2018 – Iovance Biotherapeutics had its price target raised by analysts at HC Wainwright from $16.00 to $22.00. They now have a “buy” rating on the stock.
  • 1/22/2018 – Iovance Biotherapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital.
  • 1/20/2018 – Iovance Biotherapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. “
  • 1/20/2018 – Iovance Biotherapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 1/17/2018 – Iovance Biotherapeutics was given a new $16.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 1/17/2018 – Iovance Biotherapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $10.00 price target on the stock. According to Zacks, “Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. “
  • 1/4/2018 – Iovance Biotherapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. “
  • 1/3/2018 – Iovance Biotherapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $9.00 price target on the stock. According to Zacks, “Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. “
  • 12/22/2017 – Iovance Biotherapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

Shares of Iovance Biotherapeutics Inc (NASDAQ IOVA) opened at $17.40 on Thursday. The company has a market capitalization of $1,415.22, a price-to-earnings ratio of -13.38 and a beta of 5.89. Iovance Biotherapeutics Inc has a 1-year low of $4.45 and a 1-year high of $18.15.

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Receive News & Ratings for Iovance Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply